NASDAQ: DYAIDyadic International Inc Stock
$1.23-0.01 (-0.81%)
Updated Apr 17, 2025
DYAI Price
$1.23
Fair Value Price
N/A
Market Cap
$37.01M
52 Week Low
$0.93
52 Week High
$2.67
P/E
-6.15x
P/B
14.98x
P/S
14.68x
PEG
N/A
Dividend Yield
N/A
Revenue
$3.50M
Earnings
-$5.81M
Gross Margin
65.8%
Operating Margin
-153.95%
Profit Margin
-166.2%
Debt to Equity
3.02
Operating Cash Flow
-$4M
Beta
0.77
Next Earnings
May 12, 2025
Ex-Dividend
N/A
Next Dividend
N/A
DYAI Overview
Dyadic International, Inc., a biotechnology platform company, develops, produces, and sells enzymes and other proteins in the United States. The company utilizes its patented and proprietary C1 platform and other technologies to conduct research, development, and commercial activities for the development and manufacturing of human and animal vaccines and drugs, such as virus like particles and antigens, monoclonal antibodies, bi/tri-specific antibodies, fab antibody fragments, Fc-fusion proteins, biosimilars and/or biobetters, and other therapeutic enzymes and proteins. It offers DYAI-100, SARS-CoV-2-RBD antigen vaccine candidate towards a first-in-human Phase 1 clinical trial, is to validate to serve as proof of concept for the development of next generation multivariant COVID-19 vaccine candidates. The company has a research and development agreement with VTT Technical Research Centre of Finland, Ltd.; strategic research services agreement with Biotechnology Developments for Industry in Pharmaceuticals, S.L.U.; and collaboration with Syngene International Limited. Dyadic International, Inc. was founded in 1979 and is headquartered in Jupiter, Florida.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine DYAI's potential to beat the market
- DYAI doesn't meet the minimum data requirements for our proprietary Zen Ratings model. Learn more about Zen Ratings.
Zen Rating Component Grades
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
DYAI
RankedUnranked of 463
RankedUnranked of 463
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $2.61 | A | |
| $7.75 | A | |
| $16.85 | A |
Be the first to know about important DYAI news, forecast changes, insider trades & much more!
DYAI News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how DYAI scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
DYAI is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
DYAI is poor value based on its book value relative to its share price (14.98x), compared to the US Biotechnology industry average (4.05x)
P/B vs Industry Valuation
DYAI is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more DYAI due diligence checks available for Premium users.
Valuation
DYAI fair value
Fair Value of DYAI stock based on Discounted Cash Flow (DCF)
Price
$1.23
Fair Value
-$0.21
Undervalued by
675.52%
DYAI is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
DYAI price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-6.15x
Industry
-177.72x
Market
27.98x
DYAI price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
14.98x
Industry
4.05x
DYAI is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
DYAI's financial health
Profit margin
Revenue
$817.4k
Net Income
-$1.6M
Profit Margin
-189.7%
DYAI's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
DYAI's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$9.9M
Liabilities
$7.5M
Debt to equity
3.02
DYAI's short-term assets ($9.83M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
DYAI's short-term assets ($9.83M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
DYAI's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
DYAI's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$696.4k
Investing
$1.3M
Financing
$24.3k
DYAI's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
DYAI vs Biotech Stocks
Dyadic International Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.